Replies to post #148057 on Biotech Values

[mcbio]

Hasn't it been stuck in pre clin for a long time?

I don't believe so. As stated in #msg-79157547, AZD3293 is the successor BACE inhibitor to AZD3839 upon the Phase 1 results of the latter. Clinicaltrials.gov reports the Phase 1 trial for AZD3839 was complete in November 2011 after a June 2011 start. So, presumably further work had to be done on AZD3293 after those November 2011 results from the first BACE inhibitor to improve upon it.